Sept 8 (Reuters) - Catabasis Pharmaceuticals Inc :
* CATABASIS PHARMACEUTICALS ANNOUNCES NEW COMPANY NAME, ASTRIA THERAPEUTICS
* CATABASIS PHARMACEUTICALS INC - EXPECTS TO BEGIN TRADING UNDER NEW TICKER SYMBOL "ATXS" ON NASDAQ GLOBAL SELECT MARKET AT MARKET OPEN ON SEPTEMBER 9
* CATABASIS PHARMACEUTICALS INC - EXPECTS TO FILE IND APPLICATION FOR STAR-0215 IN MID-2022
* CATABASIS PHARMACEUTICALS - PLANS TO INITIATE PHASE 1 CLINICAL TRIAL WITH INITIAL PROOF OF CONCEPT RESULTS ANTICIPATED BY YEAR END 2022 FOR STAR-0125
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。